業(yè)執(zhí)照.jpg)
冬凌草甲素
分析標(biāo)準(zhǔn)品,HPLC≥98%
Oridonin
CAS號(hào)：28957-04-2
分子式：C20H28O6
分子量：364.43
MDL：MFCD00221762
貨號(hào) | 規(guī)格/參數(shù)/品牌 | 價(jià)格 | 貨期 |
YJ-B20310-20mg | 分析標(biāo)準(zhǔn)品,HPLC≥98% | ￥350.00 | 現(xiàn)貨 |
JS28299-100mg | 98% | ￥600.00 | 現(xiàn)貨 |
JS28299-1g | 98% | ￥2150.00 | 現(xiàn)貨 |
JS28299-5g | 98% | ￥6200.00 | 現(xiàn)貨 |
A10325-20mg | 分析標(biāo)準(zhǔn)品,含量94.8%，可溯源 | ￥1600.00 | 現(xiàn)貨 |
產(chǎn)品介紹
Oridonin是從Rabdosia rubescens中得到的二萜，是一種AKT抑制劑，對(duì) AKT1 和 AKT2 的IC50值分別為 8.4 和 8.9 μM，具有抗菌、抗炎、抗腫瘤等功效。
熔點(diǎn)：248-250℃
沸點(diǎn)：599.8℃ at 760 mmHg
比旋光度：(c, 0.1 in EtOH)-47
外觀：淡黃色針狀結(jié)晶
溶解性：DMSO:62.5mg/mL(171.50mM;Needultrasonic)
儲(chǔ)存條件：2-8℃
注意：部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。
參考文獻(xiàn)(46篇)
46. [IF=6.8] Kong Jiahui et al."Biomimetic MOFs Nanoparticles Co-Delivering Oridonin and siRNA for Synergistic Therapy in Melanoma via ferroptosis pathway."Journal of Science-Advanced Materials and Devices.2025 Jul;:100957
45. [IF=5.4] Junli Zhang et al."Screening Isodon rubescens-Derived Vesicles Harvested at Different Periods as Carriers for the Treatment of Colitis-Associated Cancer."ACS Biomaterials Science & Engineering.2025;XXXX(XXX):XXX-XXX
44. [IF=3] Jushuang Li et al."Oridonin ameliorates renal fibrosis in diabetic nephropathy by inhibiting the Wnt/β-catenin signaling pathway."RENAL FAILURE.
43. [IF=6] Mengting Li et al."Design, synthesis, and biological evaluation of oridonin derivatives as novel NLRP3 inflammasome inhibitors for the treatment of acute lung injury."EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY.2024 Aug;:116760
42. [IF=1.8] Gengzhen Huang et al."Oridonin attenuates diabetes?induced renal fibrosis via the inhibition of TXNIP/NLRP3 and NF?κB pathways by activating PPARγ in rats."EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES".2024 May;0:
41. [IF=14.5] Mengru Cai et al."An iron-based metal-organic framework nanoplatform for enhanced ferroptosis and oridonin delivery as a comprehensive antitumor strategy."Acta Pharmaceutica Sinica B".2024 May;:
40. [IF=4.6] Tianming Lu et al."Inhibition of ALDOA and ENO1-mediated Glycolysis of Oridonin as a Novel Anti-tumor Strategy of Non-small Cell Lung Cancer."Advanced Therapeutics".2024 Apr;:2400027
39. [IF=5] Shiying Ye et al."Oridonin promotes RSL3-induced ferroptosis in breast cancer cells by regulating the oxidative stress signaling pathway JNK/Nrf2/HO-1."EUROPEAN JOURNAL OF PHARMACOLOGY".2024 Apr;:176620
38. [IF=3.8] Zhang Feifan et al."Oridonin-induced ferroptosis and apoptosis: a dual approach to suppress the growth of osteosarcoma cells."BMC CANCER".2024 Dec;24(1):1-11
37. [IF=4.5] Lunji Wang et al."Antibacterial Mechanisms and Antivirulence Activities of Oridonin against Pathogenic Aeromonas hydrophila AS 1.1801."Microorganisms".2024 Feb;12(2):415
36. [IF=9.965] Mengru Cai et al."Enhanced lysosomal escape of cell penetrating peptide-functionalized metal-organic frameworks for co-delivery of survivin siRNA and oridonin."JOURNAL OF COLLOID AND INTERFACE SCIENCE.2023 Apr;:
35. [IF=2.602] ZHOU Wei et al."Preparation and characterization of an oridonin and γ-cyclodextrin complex."Food Science and Technology.2022 Aug;42:
34. [IF=5.811]
33. [IF=2.248] Yang Huiyu et al."Selective synergistic anticancer effects of cisplatin and oridonin against human p53-mutant esophageal squamous carcinoma cells."Anti-Cancer Drug. 2022 Jan;33(1):e444-e452
32. [IF=2.447] Yun Gui et al."Oridonin improves the therapeutic effect of lentinan on lung cancer."Exp Ther Med. 2021 Aug;22(2):1-9
31. [IF=3] Qu Lala et al."Phenotypic assessment and ligand screening of ETA/ETB receptors with label-free dynamic mass redistribution assay."N-S Arch Pharmacol. 2020 Jun;393(6):937-950
30. [IF=3.361] Mengru Cai et al."Functionalization of MOF-5 with mono-substituents: effects on drug delivery behavior."Rsc Adv. 2020 Oct;10(60):36862-36872
29. [IF=3.503] Lili Tian et al."Preliminary safety assessment of oridonin in zebrafish."Pharm Biol. 2019;57(1):632-640
28. [IF=3.591] Mengru Cai et al."Amino-functionalized Zn metal organic frameworks as antitumor drug curcumin carriers."New J Chem. 2020 Oct;44(41):17693-17704
27. [IF=6.543] Hong Mu-keng et al."Oridonin Alters Hepatic Urea Cycle via Gut Microbiota and Protects against Acetaminophen-Induced Liver Injury."Oxid Med Cell Longev. 2021;2021:3259238
26. [IF=0] Gan Zhao et al."Oridonin attenuates the release of pro-inflammatory cytokines in lipopolysaccharide-induced RAW264.7 cells and acute lung injury."Oncotarget. 2017 Sep 15; 8(40): 68153–68164
25. [IF=1.785] Tao Xu et al."Oridonin enhances in vitro anticancer effects of lentinan in SMMC?7721 human hepatoma cells through apoptotic genes."Exp Ther Med. 2017 Nov;14(5):5129-5134
24. [IF=2.833] Tian Lili et al."Antiangiogenic effects of oridonin."Bmc Complem Altern M. 2017 Dec;17(1):1-15
23. [IF=3.361] Jushuang Li et al."Oridonin protects against the inflammatory response in diabetic nephropathy by inhibiting the TLR4/p38-MAPK and TLR4/NF-κB signaling pathways."Int Immunopharmacol. 2018 Feb;55:9
22. [IF=3.571] Xiangling Xiao et al."Oridonin inhibits gefitinib-resistant lung cancer cells by suppressing EGFR/ERK/MMP-12 and CIP2A/Akt signaling pathways."Int J Oncol. 2016 Jun;48(6):2608-2618
21. [IF=3.723] Yang Sun et al."Oridonin prevents epithelial-mesenchymal transition and TGF-β1-induced epithelial-mesenchymal transition by inhibiting TGF-β1/Smad2/3 in osteosarcoma."Chem-Biol Interact. 2018 Dec;296:57
20. [IF=5.722] Liu Qian-Qian et al."Oridonin inhibits pancreatic cancer cell migration and epithelial-mesenchymal transition by suppressing Wnt/β-catenin signaling pathway."Cancer Cell Int. 2016 Dec;16(1):1-8
19. [IF=5.959] Lu Ying et al."Oridonin exerts anticancer effect on osteosarcoma by activating PPAR-γ and inhibiting Nrf2 pathway."Cell Death Dis. 2018 Jan;9(1):1-16
18. Tian, L., Xie, K., Sheng, D. et al. Antiangiogenic effects of oridonin. BMC Complement Altern Med 17, 192 (2017). https:##doi.org/10.1186/s12906-017-1706-3
17. Zhao G, Zhang T, Ma X, et al. Oridonin attenuates the release of pro-inflammatory cytokines in lipopolysaccharide-induced RAW264.7 cells and acute lung injury. Oncotarget. 2017;8(40):68153-68164. Published 2017 Jul 12. doi:10.18632/oncotarget.19249
16. Xiao, X., He, Z., Cao, W., Cai, F., Zhang, L., Huang, Q., Fan, C., Duan, C., Wang, X., Wang, J., Liu, Y."Oridonin inhibits gefitinib-resistant lung cancer cells by suppressing EGFR/ERK/MMP-12 and CIP2A/Akt signaling pathways". International Journal of Onco
15. Yang Sun, Xiubo Jiang, Ying Lu, Jianwei Zhu, Lisha Yu, Bo Ma, Qi Zhang, Oridonin prevents epithelial-mesenchymal transition and TGF-β1-induced epithelial-mesenchymal transition by inhibiting TGF-β1/Smad2/3 in osteosarcoma, Chemico-Biological Interactions,
14. Jushuang Li, Liping Bao, Dongqing Zha, Lian Zhang, Ping Gao, Juan Zhang, Xiaoyan Wu, Oridonin protects against the inflammatory response in diabetic nephropathy by inhibiting the TLR4/p38-MAPK and TLR4/NF-κB signaling pathways, International Immunopharmaco
13. Cai, Mengru, et al. "Amino-functionalized Zn metal organic frameworks as antitumor drug curcumin carriers." New Journal of Chemistry 44.41 (2020): 17693-17704.DOI https:##doi.org/10.1039/D0NJ03680C
12. 王倩,糾敏,孟媛媛,孔銘杰,殷成芮,汪倫記.冬凌草甲素/殼聚糖復(fù)合膜對(duì)冰鮮雞胸肉的保鮮效果[J].食品與機(jī)械,2021,37(03):125-130.
11. 李崢, 王強(qiáng), 張曉莉. 藍(lán)萼香茶菜提取溶劑的選擇及其耐缺氧作用研究[J]. 中華中醫(yī)藥學(xué)刊, 2012, 030(006):1375-1377.
10. 何中維 肖香玲 蔡芬 張亮 黃秋月 段超 劉瑩.冬凌草甲素逆轉(zhuǎn)人胃癌細(xì)胞SGC 7901/DDP順鉑耐藥的作用及機(jī)制研究[J].湖北醫(yī)藥學(xué)院學(xué)報(bào) 2016 35(03):261-265+226.
9. 尚曙玉 張鐵山 郝海軍 等. 冬凌草甲素磷脂復(fù)合物不同制劑在SD大鼠體內(nèi)生物利用度的比較[J]. 中藥材 2019 v.42;No.422(04):170-173.
8. 杜利月 郭留城 郝海軍 等. 冬凌草甲素滲透泵片制備工藝研究及體外評(píng)價(jià)[J]. 中藥材 2018 v.41；No.407(01):173-176.
7. 田麗莉 盛東來(lái) 朱國(guó)福. 冬凌草甲素抑制血管生成活性及作用機(jī)制[J]. 中國(guó)實(shí)驗(yàn)方劑學(xué)雜志 2016 022(005):166-171.
6. 糾敏 閆鵬 閆國(guó)慶 等. 冬凌草甲素對(duì)金黃色#葡萄*球菌的抑菌作用機(jī)制[J]. 江蘇農(nóng)業(yè)科學(xué) 2019 47(07):202-206.
5. 糾敏 閆鵬 李晶晶 等. 冬凌草甲素對(duì)金黃色#葡萄*球菌生物膜的抑制機(jī)制[J]. 微生物學(xué)通報(bào) 2020 v.47(05):250-256.
4. 田麗莉 朱國(guó)福 盛東來(lái). 冬凌草甲素對(duì)人臍靜脈內(nèi)皮細(xì)胞的抑制作用[J]. 溫州醫(yī)學(xué)院學(xué)報(bào) 2017 047(012):880-883 887.
3. 肖香玲 何中維 黃秋月 季娟麗 張?jiān)骑w 劉瑩.冬凌草甲素下調(diào)EGFR/ERK/MMP-12和CIP2A/Akt信號(hào)通路抑制gefitinib耐受的非小細(xì)胞肺癌的轉(zhuǎn)移[J].湖北醫(yī)藥學(xué)院學(xué)報(bào) 2016 35(06):536-542+629.
2. 糾敏 孟媛媛 王倩 等. 冬凌草甲素/殼聚糖復(fù)合膜的性能和結(jié)構(gòu)表征[J]. 食品與發(fā)酵工業(yè) 2019 045(024):119-123.
1. 汪倫記 許美秋 糾敏 等. 冬凌草提取物對(duì)金黃色#葡萄*球菌生物膜形成的抑制作用[J]. 天然產(chǎn)物研究與開(kāi)發(fā) 2017 029(006):1000-1005.
從2011年開(kāi)始我們致力于在生命科學(xué)領(lǐng)域、生物醫(yī)學(xué)實(shí)驗(yàn)技術(shù)及論文潤(rùn)色服務(wù)，協(xié)助客戶各類實(shí)驗(yàn)服務(wù)及論文潤(rùn)色十余年，是客戶您值得信賴的科研合作伙伴!
如果您受時(shí)間、試驗(yàn)條件等限制而無(wú)法完成您的課題研究，歡迎您與我們聯(lián)系。
實(shí)驗(yàn)技術(shù)服務(wù)：
